What happens when blood or marrow is used for joint care?

How is platelet-rich plasma, or PRP, prepared?

PRP stands for platelet-rich plasma, a small portion gathered by spinning blood taken from your arm. That prepared blood is then used at the sore joint. The arm and joint may feel tender in different places.

Remember this much: PRP starts with your blood.

How is bone marrow concentrate prepared?

BMAC stands for bone marrow aspirate concentrate, which is made by taking marrow at the pelvis and spinning it. The prepared marrow is then used at the joint. You'll need care directions for both the pelvis and the treated joint. Don't leave without asking how each area will be numbed and covered.

BMAC adds a marrow draw to the visit.

What does QC Kinetix offer during this visit?

QC Kinetix uses the name regenerative treatments for its non-surgical blood and marrow procedures. Its medical providers are licensed clinic staff who review your joint, history, and goals. Biologic therapies is another name for care using a prepared part of the body. Orthobiologics is the group name for procedures using blood, marrow, or other body tissue.

Ask what would be used, then ask why it suits the soreness.

What do you need before going home?

Find out whether you can drive and how much walking is allowed. Get directions for bathing, medicine, and the first night. You'll need a number for new warmth, fever, swelling, or rising pain. Ask when gentle movement may begin.

Don't leave until the home instructions make sense.

Sources

1. A double-blind randomized trial allocated 192 patients with KL 1-3 knee OA to three weekly injections of leukocyte-RICH or leukocyte-POOR PRP (mean leukocyte concentration 7,991 x10^6/L vs 0.1 x10^6/L). No difference was found in any clinical score at 2, 6 or 12 months (IKDC improved 45.6 to 60.7 vs 46.8 to 62.9; P=.626). Mild adverse events were numerically more frequent with leukocyte-rich PRP (12.2% vs 4.7%) but not significantly so.

   Di Martino A, et al. — Leukocyte-Rich versus Leukocyte-Poor Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Double-Blind Randomized Trial.. American Journal of Sports Medicine, 2022. DOI: 10.1177/03635465211064303.

2. A systematic review of 32 studies comparing leukocyte-poor and leukocyte-rich PRP in knee OA found both formulations improved pain and function above the MCID with no significant difference between them at 3, 6 or 12 months - but leukocyte-RICH PRP carried significantly higher odds of post-injection pain (OR 1.64; 95% CI 1.29-2.10) and swelling (OR 1.56; 95% CI 1.22-1.99).

   Kim JH, et al. — Adverse Reactions and Clinical Outcomes for Leukocyte-Poor Versus Leukocyte-Rich Platelet-Rich Plasma in Knee Osteoarthritis: A Systematic Review and Meta-analysis.. Orthopaedic Journal of Sports Medicine, 2021. DOI: 10.1177/23259671211011948.

3. A meta-analysis of 6 RCTs (860 patients, 334 receiving BMAC) found overall complication rates of 41.91% for BMAC versus 41.25% for comparator injectables (P=0.85), with knee effusion the commonest BMAC complication at 18.26%. Early and late complication rates did not differ significantly from HA, steroids, PRP, SVF, MSC or saline. The number needed to harm for BMAC relative to other injections was 152.

   Fucaloro S, et al. — Complication rates of bone marrow aspirate concentrate injections versus other injectable therapies for knee osteoarthritis: A systematic review and meta-analysis.. Journal of Orthopaedics, 2025. DOI: 10.1016/j.jor.2024.10.005.

4. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature Medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

5. A Danish register study of all intra-articular procedures performed on Funen over eight years measured the frequency of septic arthritis within 14 days of a glucocorticoid injection as LOW, under a local protocol using a non-touch sterile technique with patients advised to seek care on suspicion of infection.

   Petersen SK, et al. — Low frequency of septic arthritis after arthrocentesis and intra-articular glucocorticoid injection.. Scand J Rheumatol, 2019. DOI: 10.1080/03009742.2019.1584329.